Related Experiment Video
Updated: Jul 18, 2025

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
BH3 Mimetic Peptides: An Effective Strategy to Complement Anticancer Therapy
Sundra Dhakshinamurthy Saraswathy1, Arumugam Mirunalini2, Kandasamy Karthikeyan2
1Department of Biomedical Science, Bharathidasan University, Tiruchirappalli, 620 024, Tamil Nadu, India.
Abstract:
Apoptosis, a natural process of programmed cell death, is a promising therapeutic target as the disruption of apoptosis evolves in many diseases including cancer. Several pieces of evidence indicate that errors in apoptotic pathways result in the imbalance between cell proliferation and death, allowing cells with genetic abnormalities to survive. The intrinsic and extrinsic pathways of apoptosis utilize different caspases to execute the event of cell death through the cleavage of hundreds of proteins. Proteins from the Bcl-2 family, a pivotal component of the mitochondrial apoptosis pathway, activate the death signal either directly or indirectly involving mitochondrial translocation of Bax/Bak, which are recognized critical elements in defective apoptosis. The majority of chemotherapeutic drugs destroy cancer cells by activating the apoptotic machinery via Bcl-2/Bax-dependent process and failure of which leads to an intrinsic chemoresistance. Recent insights into the dynamic action of pro-survival Bcl-2 proteins in cancer pathogenesis and resistance has set the stage for the development of small molecules as Bcl-2 antagonist and modulators of apoptosis. The BH3-only proteins are vital inducers of the mitochondrial apoptosis mechanism that operate either by assuming the functional activity of the proapoptotic Bcl-2 family members or by impeding the antiapoptotic Bcl-2 proteins. Based on the structural interaction studies between the proapoptotic and anti-apoptotic proteins, several synthetic peptides have been designed to functionally mimic the BH3 domain, targeting directly the pro-survival Bcl-2 proteins. The "BH3-peptide mimetics" a novel class of Bcl-2 protein antagonists essentially play an important role in the treatment of malignancies as they are predicted to persuade non-receptor mediated programmed cell death. This review summarizes the most promising BH3-peptide mimetic compounds that function as selective antagonists of Bcl-2 proteins and would be effective in treating various cancers.
Insights
Targeting apoptosis, a programmed cell death process, is key for cancer therapy. BH3-peptide mimetics offer a novel approach by antagonizing Bcl-2 proteins to induce cancer cell death.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- Apoptosis, or programmed cell death, is crucial for maintaining cellular balance, and its dysregulation is implicated in diseases like cancer.
- Defects in apoptotic pathways, particularly involving the Bcl-2 protein family, contribute to cancer development and chemoresistance.
- The Bcl-2 family regulates mitochondrial apoptosis, with pro-survival and pro-apoptotic members (like Bax/Bak) controlling cell death.
Conclusions:
- BH3-peptide mimetics represent a promising new class of drugs for cancer therapy.
- Targeting Bcl-2 proteins with these mimetics can induce programmed cell death in cancer cells.
- Further development of BH3-peptide mimetics holds significant potential for effective cancer treatment.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

